

# TP53 (17p13) Orange FISH Probe

Control Number: 901-7306-101416

**BIOCARE**  
M E D I C A L  
ISO  
9001&13485  
CERTIFIED

**Catalog Number:** HFI7306A  
**Description:** TP53 (17p13) Orange FISH Probe  
**Dilution:** Ready-to-use  
**Volume:** 100 µL

**Intended Use:**  
For In Vitro Diagnostic Use.

TP53 (17p13) Orange FISH Probe is intended to hybridize to the 17p13 region on chromosome 17. The clinical interpretation of any positive or negative hybridization events should be complemented by the use of appropriate controls and other diagnostic tests where appropriate. Evaluation should be carried out within the context of the patient's clinical history by a qualified pathologist.



## FOR DISTRIBUTION OUTSIDE THE UNITED STATES ONLY

### Summary and Explanation:

TP53 is the gene which encodes for the p53 tumor suppressor protein. TP53 is activated in many forms of cellular stress including carcinogenesis and exerts multiple anti-proliferative functions<sup>1</sup>. TP53 mutations are one of the most common findings in many human cancers and has been proposed as an effective measure of prognosis<sup>2</sup>. Typically the presence of a specific mutation has been correlated with a shorter survival or poor response to treatment. Multiple breast cancer studies have all shown that there was a clear association between mutation and bad prognosis<sup>3</sup>.

### Principle of Procedure:

The TP53 (17p13) Probe is approximately 325 kb in size and is designed to provide coverage of the 17p13 region of chromosome 17.



TP53 (17p13) Orange FISH probe hybridized on normal blood sample. Interphase and metaphase cellular states are shown.

**Species Reactivity:** Human

### Known Application:

Fluorescence In-Situ Hybridization (FISH) on hematological samples.

**Supplied As:** Probe in hybridization buffer.

### Storage and Stability:

Store probe at -20°C and away from light. The product is stable to the expiration date printed on the label, when stored under these conditions. Do not use after expiration date.

### Protocol Recommendations:

1. Apply 10 µl of probe mix to the selected target area of the slide.
2. Cover with an 18 mm x 18 mm cover glass and seal with rubber cement.
3. Place sealed slide on thermal cycler designed to perform denaturation and hybridization steps in slide-based FISH procedures (please see manufacturer's operating instructions).
4. Denature probe at 72°C for 2 minutes and hybridize at 37°C between 12-18 hours.
5. Remove cover glass and wash slides using the following conditions:
  - 5.1. Wash 1: 0.4x SSC/0.3% Nonident-P40 at 72°C±1°C for 2 minutes
  - 5.2. Wash 2: 2x SSC/0.1% Nonident-P40 at room temperature for 2 minutes
6. Apply 10 µl of a DAPI nuclear counterstain directly to the target area of the slide; cover area using a 24 mm x 50 mm cover glass.
7. Slides are ready for visualization using a fluorescent microscope.

### Technical Note:

Biocare Medical FISH probes are optimized to provide the best signal performance using optical filters that can accommodate the excitation/emission wavelengths specified below. Using filters outside these spectral specifications may produce sub-optimal results.

Fluorophore	Excitation (nm)	Emission (nm)
AQUA	432	472
GREEN	498	521
ORANGE	546	575
RED	593	618

### Limitations:

The optimum probe dilution and protocols for specific applications may vary. These include, but are not limited to; sample preparation, hybridization conditions and incubation times, post hybridization washes and microscope filter specifications and illumination conditions. The recommended hybridization times and wash conditions are for guidance only and it is the responsibility of the operator to determine optimal conditions. The clinical interpretation of any positive or

 Biocare Medical  
4040 Pike Lane  
Concord, CA 94520  
USA



Tel: 800-799-9499 | www.biocare.net | Fax: 925-603-8080  
Rev: 091516

 EMERGO EUROPE  
Molenstraat 15  
2513 BH, The Hague  
The Netherlands

# TP53 (17p13) Orange FISH Probe

Control Number: 901-7306-101416

**BIOCARE**  
M E D I C A L  
ISO  
9001&13485  
CERTIFIED

negative hybridization events should be evaluated within the context of clinical presentation, morphological and/or cytogenetic criteria by a suitably qualified practitioner. These findings should be complemented by the use of appropriate controls and other diagnostic tests where appropriate.

## Quality Control:

Fluorescence In-Situ Hybridization (FISH) Methods for Clinical Laboratories; Approved Guidelines – Second edition (MM07-A2). CLSI, Wayne, PA ([www.clsi.org](http://www.clsi.org)). 2013.

## Precautions:

1. This product contains formamide, which may be toxic. Formamide may cause serious eye damage or reproductive toxicity. It may also cause irritation by inhalation or skin contact. Avoid any direct contact exposure to reagent. Take appropriate protective measures (use disposable gloves, protective glasses, and lab garments).
2. Specimens, before and after fixation, and all materials exposed to them should be handled as if capable of transmitting infection and disposed of with proper precautions. Never pipette reagents by mouth and avoid contacting the skin and mucous membranes with reagents and specimens. If reagents or specimens come in contact with sensitive areas, wash with copious amounts of water<sup>4</sup>.
3. The SDS is available upon request and is located at <http://biocare.net/>.

## Troubleshooting:

Follow the FISH probe specific protocol recommendations according to data sheet provided. If atypical results occur, contact Biocare Medical's Technical Support at 1-800-542-2002.

## References:

1. Vogelstein B, Lane D, Levine AJ. (2000). Surfing the p53 network. *Nature* 408: 307–310.
2. Hainaut P, Hollstein M. (2000). p53 and human cancer: the first ten thousand mutations. *Adv Cancer Res* 77: 81–137.
3. Olivier M, Langerod A, Carrieri P, Bergh J, Klaar S, Eyfjord J et al. (2006). The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. *Clin Cancer Res* 12: 1157–1167.
4. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory workers from occupationally Acquired Infections; Approved Guideline-Fourth Edition CLSI document M29-A4 Wayne, PA 2014.

 Biocare Medical  
4040 Pike Lane  
Concord, CA 94520  
USA



Tel: 800-799-9499 | [www.biocare.net](http://www.biocare.net) | Fax: 925-603-8080  
Rev: 091516

 EMERGO EUROPE  
Molenstraat 15  
2513 BH, The Hague  
The Netherlands